Measures to Lower the Stress Response in Pediatric Cardiac Surgery
NCT00848393 is a phase 2 interventional trial sponsored by Nationwide Children's Hospital. As of 18 Nov 2026, it is completed. It studies Fentanyl and Fentanyl + Dexmedetomidine in Atrioventricular Septal Defects (AVSD), Tetralogy of Fallot (TOF) and 1 more condition. The registry lists an enrollment of 52 participants at 1 site in 1 country. The registry lists a start date of 30 Nov 2008 and a primary completion date of 31 Dec 2013.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00848393 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Nationwide Children's Hospital |
| Enrollment | 52 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Atrioventricular Septal Defects (AVSD), Tetralogy of Fallot (TOF) and Ventricular Septal Defects (VSD) |
| Drugs | Fentanyl and Fentanyl + Dexmedetomidine |
| Start | 30 Nov 2008 |
| Primary completion | 31 Dec 2013 |
| Study completion | 31 Dec 2013 |
| Last update posted | 27 Jul 2018 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Aymen N Naguib, MD
Nationwide Children's Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Nationwide Children's Hospital
Columbus
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00848393
Each answer restates registry values shown on this page.
What is NCT00848393?
NCT00848393 is a phase 2 interventional trial sponsored by Nationwide Children's Hospital. It studies Fentanyl and Fentanyl + Dexmedetomidine in Atrioventricular Septal Defects (AVSD), Tetralogy of Fallot (TOF) and 1 more condition.
Who leads NCT00848393?
The registry names Aymen N Naguib, MD (principal investigator, Nationwide Children's Hospital) as the overall official.
Where does NCT00848393 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00848393 study?
The registered drug and biological interventions are Fentanyl and Fentanyl + Dexmedetomidine.
When did NCT00848393 end?
The registry lists a primary completion date of 31 Dec 2013 and a study completion date of 31 Dec 2013. The sponsor last updated the record on 27 Jul 2018.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.